Cobo-CalvoARuizAMaillartE, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology2018; 90(21): e1858–e1869, https://pubmed.ncbi.nlm.nih.gov/29695592/ (accessed 4 November 2021).
2.
RománGCGraciaFTorresA, et al. Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol2021; 12: 653786.
3.
VoyseyMClemensSACMadhiSA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet2021; 397(10269): 99–111.
4.
MealyMACookLJPacheF, et al. Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord2021; 23: 78–82, http://www.msard-journal.com/article/S2211034818301433/fulltext (accessed 1 November 2021).
5.
LotanIRomanowGLevyM. Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Mult Scler Relat Disord2021; 55: 103189.
